How many exomes with good coverage (30x) can sequenced in 454/Roche with US$ 30,000??
Unconfigured Ad
Collapse
X
-
All of the solution phase methods used for exome capture have a small insert size to increase the amount of on target sequencing. All exomes we do cheaply and well on the Illumina HiSeq. Even Roche Nimblegen's EZ exome kits are designed for the HiSeq. The solution phase work well and are easy to automate.
Roche has the 2.1M exome array that works with 454 but out of a single run with ~1.2M reads (~350 Mb) you can only get 8-9X median coverage of a single sample. For a 50 Mb exome @ 50X you can easily run eight samples in a single lane of a HiSeq for a fraction of the cost of a 454 run.
We have found the 454 better suited for 250 kb - 1Mb custom panels to use the longer reads to get better information on indels and haplotype SNPs. With the 1Mb using the 385K array ~50X median coverage using 1/4 PTP. This is useful in addition to exomes/genomes done on the HiSeq and for follow-up validation. This step likely will move to the MiSeq especially with the PE-250 coming.
Comment
-
According to Genomic version of Moore's Law...
...prices of exome sequencing should have dropped some since this thread began. Can anyone comment on whether any aspect of exome sequencing actually got cheaper in the last year?
-A
Comment
-
Hello anoopmandaher, I am a sales rep with Axeq Technologies. The prices have gone down a little bit, but not too much. You can see our current promotions at www.axeq.com
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
Today, 11:01 AM -
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 02:55 AM
|
0 responses
7 views
0 reactions
|
Last Post
by SEQadmin2
Today, 02:55 AM
|
||
|
Started by SEQadmin2, 07-24-2026, 12:17 PM
|
0 responses
11 views
0 reactions
|
Last Post
by SEQadmin2
07-24-2026, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
12 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
24 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|

Comment